Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Shirong Zhang; Wenxian Wang; Chunwei Xu; Yongchang Zhang; Xiuyu Cai; Qian Wang; Zhengbo Song; Ziming Li; Jinpu Yu; Wenzhao Zhong; Zhijie Wang; Jingjing Liu; Anwen Liu; Wen Li; Ping Zhan; Hongbing Liu; Tangfeng Lv; Liyun Miao; Lingfeng Min; Gen Lin; Long Huang; Jingping Yuan; Zhansheng Jiang; Xingxiang Pu; Chuangzhou Rao; Dongqing Lv; Zongyang Yu; Xiaoyan Li; Chuanhao Tang; Chengzhi Zhou; Junping Zhang; Hui Guo; Qian Chu; Rui Meng; Xuewen Liu; Jingxun Wu; Jin Zhou; Zhengfei Zhu; Weiwei Pan; Xiaowei Dong; Fei Pang; Kai Wang; Chao Yao; Guomin Lin; Site Li; Zhi Yang; Jiancheng Luo; Hongtao Jia; Xiuqing Nie; Liping Wang; Youcai Zhu; Xiao Hu; Yanru Xie; Xinqing Lin; Jing Cai; Yang Xia; Huijing Feng; Lin Wang; Yingying Du; Wang Yao; Xuefei Shi; Xiaomin Niu; Dongmei Yuan; Yanwen Yao; Jing Kang; Jiatao Zhang; Chao Zhang; Wenbin Gao; Jianhui Huang; Yinbin Zhang; Pingli Sun; Hong Wang; Mingxiang Ye; Dong Wang; Zhaofeng Wang; Bing Wan; Donglai Lv; Genhua Yu; Lin Shi; Yuanli Xia; Feng Gao; Xiaochen Zhang; Tao Xu; Wei Zhou; Haixia Wang; Zhefeng Liu; Nong Yang; Lin Wu; Qiming Wang; Guansong Wang; Zhuan Hong; Jiandong Wang; Meiyu Fang; Yong Fang; Yiping Zhang; Yong Song; Shenglin Ma; Wenfeng Fang; Yuanzhi Lu

doi:10.1111/1759-7714.14743

Back

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Journal article

Open access

Peer reviewed

Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer

Shirong Zhang, Wenxian Wang, Chunwei Xu, Yongchang Zhang, Xiuyu Cai, Qian Wang, Zhengbo Song, Ziming Li, Jinpu Yu, Wenzhao Zhong, …

Thoracic cancer, Vol.14(1), pp.91-104

01/2023

DOI: https://doi.org/10.1111/1759-7714.14743

PMID: 36444143

Abstract

Antineoplastic Agents - therapeutic use

Carcinoma, Non-Small-Cell Lung - diagnosis

Carcinoma, Non-Small-Cell Lung - drug therapy

Carcinoma, Non-Small-Cell Lung - genetics

Consensus

East Asian People

Humans

In Situ Hybridization, Fluorescence

Lung Neoplasms - diagnosis

Lung Neoplasms - drug therapy

Lung Neoplasms - genetics

Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. Its alterations, mainly including mutations, amplifications, and overexpression are associated with poor prognosis and are one of the major drivers in non-small cell lung cancer (NSCLC). Several clinical trials had been investigating on the treatments of HER2-altered NSCLC, including conventional chemotherapy, programmed death 1 (PD-1) inhibitors, tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs), however, the results were either disappointing or encouraging, but inconsistent. Trastuzumab deruxtecan (T-DXd) was recently approved by the Food and Drug Administration as the first targeted agent for treating HER2-mutant NSCLC. Effective screening of patients is the key to the clinical application of HER2-targeted agents such as TKIs and ADCs. Various testing methods are nowadays available, including polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), etc. Each method has its pros and cons and should be reasonably assigned to appropriate patients for diagnosis and guiding treatment decisions. To help standardize the clinical workflow, our expert group reached a consensus on the clinical management of HER2-altered NSCLC, focusing on the diagnosis and treatment strategies.

Files and links (1)

url

https://doi.org/10.1111/1759-7714.14743View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer
Creators - without role: Shirong Zhang - Zhejiang University
Wenxian Wang - Zhejiang Cancer Hospital
Chunwei Xu - Chinese Academy of Sciences
Yongchang Zhang - Hunan Cancer Hospital
Xiuyu Cai - Sun Yat-sen University Cancer Center
Qian Wang - Nanjing University of Chinese Medicine
Zhengbo Song - Zhejiang Cancer Hospital
Ziming Li - Shanghai Chest Hospital
Jinpu Yu - Tianjin Medical University Cancer Institute and Hospital
Wenzhao Zhong - Guangdong Provincial People's Hospital
Zhijie Wang - Chinese Academy of Medical Sciences & Peking Union Medical College
Jingjing Liu - Jilin Province Tumor Hospital
Anwen Liu - Second Affiliated Hospital of Nanchang University
Wen Li - Second Affiliated Hospital of Zhejiang University
Ping Zhan - Nanjing Medical University
Hongbing Liu - Nanjing Medical University
Tangfeng Lv - Nanjing Medical University
Liyun Miao - Nanjing Drum Tower Hospital
Lingfeng Min - Yangzhou University
Gen Lin - Fujian Provincial Cancer Hospital
Long Huang - Second Affiliated Hospital of Nanchang University
Jingping Yuan - Renmin Hospital of Wuhan University
Zhansheng Jiang - Tianjin Medical University Cancer Institute and Hospital
Xingxiang Pu - Hunan Cancer Hospital
Chuangzhou Rao - University of Chinese Academy of Sciences
Dongqing Lv - Wenzhou Medical University
Zongyang Yu - Fujian Medical University
Xiaoyan Li - Beijing Tian Tan Hospital
Chuanhao Tang - Peking University International Hospital
Chengzhi Zhou - First Affiliated Hospital of Guangzhou Medical University
Junping Zhang - Shanxi Academy of Medical Sciences
Hui Guo - First Affiliated Hospital of Xi'an Jiaotong University
Qian Chu - Huazhong University of Science and Technology
Rui Meng - Union Hospital
Xuewen Liu - Third Xiangya Hospital
Jingxun Wu - First Affiliated Hospital of Xiamen University
Jin Zhou - Sichuan Cancer Hospital
Zhengfei Zhu - Fudan University Shanghai Cancer Center
Weiwei Pan - Jiaxing University
Xiaowei Dong - Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China
Fei Pang - Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China
Kai Wang - Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China
Chao Yao - Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China
Guomin Lin - Department of Medical, Shanghai OrigiMed Co., Ltd, Shanghai, China
Site Li - Department of IVD Medical Marketing, 3D Medicines, Shanghai, China
Zhi Yang - Department of IVD Medical Marketing, 3D Medicines, Shanghai, China
Jiancheng Luo - Department of Medical, Aiyi Technology, Beijing, China
Hongtao Jia - Department of Medical, Aiyi Technology, Beijing, China
Xiuqing Nie - Department of Clinical Trial, Novocodex Biopharmaceutic, Shaoxing, China
Liping Wang - Baotou Medical College
Youcai Zhu - Jiaxing University
Xiao Hu - Zhejiang Cancer Hospital
Yanru Xie - Lishui Central Hospital
Xinqing Lin - First Affiliated Hospital of Guangzhou Medical University
Jing Cai - Second Affiliated Hospital of Nanchang University
Yang Xia - Second Affiliated Hospital of Zhejiang University
Huijing Feng - Shanxi Academy of Medical Sciences
Lin Wang - Shanxi Academy of Medical Sciences
Yingying Du - First Affiliated Hospital of Anhui Medical University
Wang Yao - The First Affiliated Hospital, Sun Yat-sen University
Xuefei Shi - Huzhou University
Xiaomin Niu - Shanghai Chest Hospital
Dongmei Yuan - Nanjing Medical University
Yanwen Yao - Nanjing Medical University
Jing Kang - Guangdong Academy of Medical Sciences
Jiatao Zhang - Guangdong Academy of Medical Sciences
Chao Zhang - Guangdong Academy of Medical Sciences
Wenbin Gao - Shenzhen Third People’s Hospital
Jianhui Huang - Department of Oncology, Lishui Municipal Central Hospital, Lishui, China
Yinbin Zhang - Second Affiliated Hospital of Xi'an Jiaotong University
Pingli Sun - Jilin University
Hong Wang - Chinese PLA General Hospital
Mingxiang Ye - Nanjing Medical University
Dong Wang - Nanjing Medical University
Zhaofeng Wang - Nanjing Medical University
Bing Wan - Nanjing Medical University
Donglai Lv - Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei, China
Genhua Yu - Zhebei Mingzhou Hospital
Lin Shi - Fudan University
Yuanli Xia - Jiaxing University
Feng Gao - Fourth Hospital of Hebei Medical University
Xiaochen Zhang - Zhejiang University
Tao Xu - Affiliated Hospital of Qingdao University
Wei Zhou - Chinese Academy of Sciences
Haixia Wang - Chinese Academy of Sciences
Zhefeng Liu - Chinese PLA General Hospital
Nong Yang - Hunan Cancer Hospital
Lin Wu - Hunan Cancer Hospital
Qiming Wang - Henan Cancer Hospital
Guansong Wang - Xinqiao Hospital
Zhuan Hong - Jiangsu Cancer Hospital
Jiandong Wang - Nanjing Medical University
Meiyu Fang - Zhejiang Cancer Hospital
Yong Fang - Zhejiang University
Yiping Zhang - Zhejiang Cancer Hospital
Yong Song - Nanjing Medical University
Shenglin Ma - Zhejiang University
Wenfeng Fang - Sun Yat-sen University Cancer Center
Yuanzhi Lu - First Affiliated Hospital of Jinan University
Publication Details: Thoracic cancer, Vol.14(1), pp.91-104
Identifiers: 9942010408331
Academic Unit: King Abdullah University of Science & Technology
Language: English
Resource Type: Journal article